Fluoropyrimidine-associated toxicity and DPYD variants c. 85T> C, c. 496A> G, and c. 1236G> A: impact of haplotype
S Medwid, TJ Wigle, RB Kim - Cancer Chemotherapy and Pharmacology, 2023 - Springer
Dihydropyrimidine dehydrogenase (DPYD) is the rate-limiting step in fluoropyrimidines
metabolism. Currently, genotype-guided fluoropyrimidine dosing is recommended for four …
metabolism. Currently, genotype-guided fluoropyrimidine dosing is recommended for four …
Implementation of upfront DPYD genotyping with a low-cost and high-throughput assay to guide fluoropyrimidine treatment in cancer patients
M Pinheiro, A Peixoto, P Rocha, C Santos… - Pharmacogenetics …, 2023 - journals.lww.com
Objectives Genetic variants in the dihydropyrimidine dehydrogenase (DPYD) gene are
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …
associated with reduced dihydropyrimidine dehydrogenase enzyme activity and can cause …
Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis
MJ Deenen, D Meulendijks, A Cats… - Journal of Clinical …, 2016 - ascopubs.org
Purpose Fluoropyrimidines are frequently prescribed anticancer drugs. A polymorphism in
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
the fluoropyrimidine metabolizing enzyme dihydropyrimidine dehydrogenase (DPD; ie …
Clinical Pharmacogenetics Implementation Consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing
The fluoropyrimidines are the mainstay chemotherapeutic agents for the treatment of many
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
types of cancers. Detoxifying metabolism of fluoropyrimidines requires dihydropyrimidine …
Clinical relevance of DPYD variants c. 1679T> G, c. 1236G> A/HapB3, and c. 1601G> A as predictors of severe fluoropyrimidine-associated toxicity: a systematic …
D Meulendijks, LM Henricks, GS Sonke… - The Lancet …, 2015 - thelancet.com
Background The best-known cause of intolerance to fluoropyrimidines is dihydropyrimidine
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
dehydrogenase (DPD) deficiency, which can result from deleterious polymorphisms in the …
Dihydropyrimidine dehydrogenase polymorphisms and fluoropyrimidine toxicity: ready for routine clinical application within personalized medicine?
Abstract Fluoropyrimidines, including 5-fluorouracil (5-FU), are widely used in the treatment
of solid tumors and remain the backbone of many combination regimens. Despite their …
of solid tumors and remain the backbone of many combination regimens. Despite their …
Patients carrying DPYD variant alleles have increased risk of severe toxicity and related treatment modifications during fluoropyrimidine chemotherapy
F Shakeel, F Fang, JW Kwon, K Koo… - …, 2021 - Taylor & Francis
Aim: To evaluate toxicity risk in carriers of four DPYD variants using an institutional genetic
repository. Materials & methods: Of over 65,000 patients in the repository, 582 were …
repository. Materials & methods: Of over 65,000 patients in the repository, 582 were …
Impact of pretreatment dihydropyrimidine dehydrogenase genotype‐guided fluoropyrimidine dosing on chemotherapy associated adverse events
TJ Wigle, BL Povitz, S Medwid, WA Teft… - Clinical and …, 2021 - Wiley Online Library
Consensus guidelines exist for genotype‐guided fluoropyrimidine dosing based on variation
in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not …
in the gene dihydropyrimidine dehydrogenase (DPYD). However, these guidelines have not …
A genotyping/phenotyping approach with careful clinical monitoring to manage the fluoropyrimidines-based therapy: clinical cases and systematic review of the …
V Conti, E De Bellis, V Manzo, F Sabbatino… - Journal of Personalized …, 2020 - mdpi.com
Fluoropyrimidines (FP) are mainly metabolised by dihydropyrimidine dehydrogenase (DPD),
encoded by the DPYD gene. FP pharmacogenetics, including four DPYD polymorphisms …
encoded by the DPYD gene. FP pharmacogenetics, including four DPYD polymorphisms …
Developing DPYD Genotyping Method for Personalized Fluoropyrimidines Therapy
BYL Wong, Z Li, MJ Raphael… - The Journal of …, 2024 - academic.oup.com
Background Fluoropyrimidine drugs are widely used in chemotherapy to treat solid tumors.
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …
However, severe toxicity has been reported in 10% to 40% of patients. The DPYD gene …